📅 PUBMED DAILY TRIAGE — 2026-05-07

Window: 2026-05-06T09:00:00Z → 2026-05-07T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~80 candidates | Candidates evaluated: 15 kept High priority: 3 | Standard: 12 | Low/archive: 0 kept | Unsolicited finds: 2 Run status: SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

TR-2026-05-07-001 / PMID 42092150 · Non-invasive profiling of the tumour microenvironment with spatial ecotypes · 8/10 🔴 Zhang W, Brown EL, Usmani A, et al. | Nature | DOI: 10.1038/s41586-026-10452-4

ML framework integrating >10M single-cell + spatial transcriptomes identifies 9 conserved spatial ecotypes (SEs) recoverable from plasma cfDNA via deep learning; SE levels in ~100 melanoma patients predict immunotherapy response. Landmark paper establishing non-invasive TME profiling from blood — potential paradigm shift for liquid biopsy beyond ctDNA/CTC.

AI/ML in Clinical Diagnostics and Imaging

TR-2026-05-07-002 / PMID 42091907 · Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring · 8/10 🔴 Doyle S, Oerlemans MA, et al. (Netherlands Cancer Institute + King's College London) | NPJ Breast Cancer | DOI: 10.1038/s41523-026-00957-6

Foundation model achieves AUROC 0.90/0.84/0.86 for ER/HER2/grade; multicenter Dutch (n=887) + UK (n=259) validation; NPV 0.86 for active surveillance eligibility (LORD trial context). Directly addresses DCIS overtreatment problem — clinically deployable with demonstrated generalizability.

Precision Oncology and Genomic Medicine

TR-2026-05-07-003 / PMID 42092061 · Two decades of PARP inhibitor synthetic lethality in cancer · 8/10 🟠 Lord CJ, Tutt ANJ, Ashworth A (ICR London + UCSF) | Nature | DOI: 10.1038/s41586-026-10404-y

Definitive 20-year synthesis by founding authors in Nature: BRCA-PARP synthetic lethality from discovery to approved therapy for breast, ovarian, prostate, pancreatic cancers; establishes germline BRCA1/2 as first companion diagnostic biomarker; reviews expanding synthetic lethality landscape. Essential precision oncology reference.

🟢⚪ STANDARD (4-7) — Top by Topic

Hematologic Malignancies (AML/MDS/CLL/MPN/Lymphoma)

• TR-2026-05-07-004 / PMID 42091886 · Paralog-selective p300 protein degrader in hematological malignancies · 5/10 · Drug Development | Nat Commun (AbbVie) — novel PROTAC, AML/lymphoma/MM xenograft activity, preclinical
• TR-2026-05-07-005 / PMID 42092277 · DDX28 promotes cell cycle/DNA repair + immunosuppressive TME in AML · 5/10 · Diagnostics | Transl Oncol — bioinformatics, novel prognostic biomarker, in vitro validation
• TR-2026-05-07-009 / PMID 42092292 · CAR-T access in Latin America: barriers and pathways · 5/10 · Public Health | Semin Immunol (Weill Cornell) — >90% cost reduction in pilot models, LMIC equity review 🟡
• No 8+ articles from Hematologic malignancies topic this window (best: 5/10)

Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

• TR-2026-05-07-006 / PMID 42092284 · Multimodal liquid biopsy surveillance after pancreatectomy for PDAC · 6/10 · Diagnostics | Cancer Treat Res Commun — scoping review with confirmation-gated algorithm, ctDNA/CTC/EV surveillance

AI/ML in Clinical Diagnostics and Imaging

• TR-2026-05-07-012 / PMID 42091802 · Spinal cord radiomics ML predicts meaningful improvement after DCM surgery · 5/10 · Diagnostics | J Imaging Inform Med — AUC 0.88, pilot study N=46, NIH-funded

Precision Oncology and Genomic Medicine

• TR-2026-05-07-011 / PMID 42092301 · Genetic analysis of primary lung interdigitating dendritic cell sarcomas · 5/10 · Genomics/Precision Medicine | J Pathol — WES of 9 cases, druggable targets in all tumors, rare disease

Novel Therapeutics (Immunotherapy, CAR-T, Targeted Therapy)

• TR-2026-05-07-007 / PMID 42092113 · Sarcopenia and pentraxin-3 as predictors of immunotherapy outcomes in NSCLC · 6/10 · Diagnostics | Sci Rep — first prospective evidence, N=41, pentraxin-3 as novel biomarker
• TR-2026-05-07-008 / PMID 42092267 🚩SENTINEL · Integrated perioperative host-response optimization RCT for rectal cancer · 7/10 · Treatment Innovation | Surgery — RCT N=194, DFS 92.8% vs 77.3% (HR 0.44), OS 95.9% vs 83.5% (HR 0.39), ⚠️ single-center dramatic results

Cardiovascular-Metabolic (GLP-1, SGLT2, Cardiometabolic Risk)

• TR-2026-05-07-010 / PMID 42092280 · PAR2 promotes dyslipidemia, obesity and MASLD via HNF4α repression · 5/10 · Drug Development | JHEP Rep — human n=105, novel cardiometabolic target, OA-235i pepducin inhibitor; COI noted (industry founder)
• TR-2026-05-07-013 / PMID 42092296 🚩SENTINEL · ACS associated with AKI on admission but not hospital-acquired AKI · 4/10 · Public Health | Renal Fail — N=21,328, synergistic ACS+AKI mortality effect
• No 8+ articles from Cardiovascular-Metabolic topic this window (best: 5/10)

Aging, Longevity, and Population Health

• TR-2026-05-07-014 / PMID 42091209 · Prefrontal cortical asymmetry and motor slowing with fear of falling in older women · 4/10 · Diagnostics | Psychogeriatrics — EEG study N=55, FES-I correlation with cortical markers
• No 8+ articles from Aging/Longevity topic this window (best: 4/10)

Rare Diseases with High Unmet Need

• TR-2026-05-07-011 / PMID 42092301 (see above, cross-listed)
• No 8+ articles from Rare Diseases topic this window (best: 5/10)

💡 UNSOLICITED FINDS

TR-2026-05-07-008 / PMID 42092267 — Sentinel find from broad clinical outcomes scan. RCT of integrated perioperative host-response optimization (stress/sleep/nutrition) for rectal cancer surgery. Remarkable DFS and OS improvement but from a single Chinese center with only 2 listed authors and very dramatic effect sizes (HR 0.39 for OS). Phase 2 should flag for independent critical appraisal.

TR-2026-05-07-013 / PMID 42092296 — Sentinel find. Large retrospective ACS-AKI co-morbidity study confirming on-admission AKI (not hospital-acquired) as the key intersection with ACS mortality.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 6 articles
• Drug Development: 3 articles
• Treatment Innovation: 2 articles
• Genomics/Precision Medicine: 1 article
• Public Health: 2 articles
• Other: 1 article

By evidence maturity:

• Exploratory: 13 articles
• Validated: 2 articles (TR-2026-05-07-002, TR-2026-05-07-003)
• Potentially Practice-Changing: 0 articles

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed 15 | preprint 0

Topics with zero 8+ articles this run: Hematologic malignancies, CBC/ML hematology, Novel therapeutics (standalone), Cardiovascular-metabolic, Aging/longevity, Rare diseases

🔧 RUN NOTES

• No window expansion triggered: 15 articles across all topics exceeds the minimum threshold of 5.
• CBC/ML hematology: 15th consecutive empty high-priority window. Only 1 raw result in window today. Monitoring for emerging publications — topic remains high-priority watchlist.
• Aging/longevity: humans[MeSH] filter operational and effective per 2026-05-04 protocol; reduced non-human noise significantly. Best candidate scored 4/10 today.
• Cardiovascular-metabolic: 142 raw results but dominated by observational/nutrition studies; no GLP-1 or SGLT2 RCT results in window. High noise rate continuing.
• Notable exclusion: PMID 42092047 (Leukemia journal) — excluded as Editorial Expression of Concern for prior published paper on BTK/MNK inhibitor; not original research per exclusion rules.
• Sentinel flag (TR-2026-05-07-008): Perioperative RCT rectal cancer — dramatic single-center results warrant Phase 2 critical appraisal before pipeline escalation.
• Two Nature papers today (42092150, 42092061): Both landmark-class publications. Phase 2 pipeline should prioritize full-text review.
• Rolling 7-day zero HIGH topics: CBC/ML hematology (15 consecutive), Aging/longevity (4 consecutive), Cardiovascular-metabolic (3 consecutive)